Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Exchange Rate Effect (2023 - 2025)

Historic Exchange Rate Effect for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $222000.0.

  • NewAmsterdam Pharma's Exchange Rate Effect fell 9511.01% to $222000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year decrease of 2317.86%. This contributed to the annual value of -$6.8 million for FY2024, which is 23463.97% down from last year.
  • Per NewAmsterdam Pharma's latest filing, its Exchange Rate Effect stood at $222000.0 for Q3 2025, which was down 9511.01% from $8.8 million recorded in Q2 2025.
  • NewAmsterdam Pharma's Exchange Rate Effect's 5-year high stood at $8.8 million during Q2 2025, with a 5-year trough of -$7.9 million in Q4 2024.
  • For the 3-year period, NewAmsterdam Pharma's Exchange Rate Effect averaged around $1.2 million, with its median value being $222000.0 (2025).
  • In the last 5 years, NewAmsterdam Pharma's Exchange Rate Effect tumbled by 930160.81% in 2024 and then surged by 107095.71% in 2025.
  • Over the past 3 years, NewAmsterdam Pharma's Exchange Rate Effect (Quarter) stood at $5.2 million in 2023, then plummeted by 252.05% to -$7.9 million in 2024, then soared by 102.8% to $222000.0 in 2025.
  • Its Exchange Rate Effect stands at $222000.0 for Q3 2025, versus $8.8 million for Q2 2025 and $3.8 million for Q1 2025.